JERSUSALEM and NEEDHAM, Massachusetts, December 3 /PRNewswire-FirstCall/-- Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN) today announced that theBavarian Red Cross has chosen Microcap(R) portable capnographs for its RTW(Rettungswagen) medical vehicles. The use of capnography can help paramedicteams to assess the ventilation status of a patient as well as alert them toissues that affect respiratory status such as displaced endotracheal tubes,episodes of respiratory depression as well as the status of resuscitativeefforts. Immediate treatment of these developing conditions can improve thepatient's status and limit the danger of further serious complications.
Since 2007, the DIN 1789 Norm and Rules for German Ambulance Vehicles ofthe type "RTW" mandated the use of capnometers when transporting emergencypatients. The Bavarian Red Cross has been looking for a standalone capnographunit to fulfill the requirements of DIN 1789, as it believed the utility vs.cost to be better than incorporating capnography into existing Defibrillatorsor Respirators. Furthermore a significant graph of the CO2 curve was arequirement.
The Bavarian Red Cross tested four different competitive units at fourdifferent sites and after a thorough analysis, chose the Oridion Microcapcapnography monitor. Their selection of the Microcap was based on severalcriteria including: ease of use, reliability, portability, ruggedness andstability of the device. Microcap monitors are one of the Oridion family ofportable monitors employing Microstream capnography technology to provideaccurate, continuous monitoring on intubated and non-intubated patients fromneonate to adult patients in hospital and pre-hospital environments,including emergency transport.
The ability to accurately monitor CO2 levels in a patient's breathing isvital for ensuring patient safety - especially in emergency transports.Studies have shown that capnography is an important tool during emergencyapplications. It has proven far superior in recognizing displacedendotracheal tubes when compared to traditional clinical subjectiveevaluations. Other studies show that etCO2 levels should be monitoredduring CPR (Cardiopulmonary resuscitation) and should be regarded as havingimportant prognostic value in predicting the outcome of resuscitativeefforts.
Capnography is increasingly being used by paramedics worldwide to help intheir assessment and real-time treatment of both intubated and non-intubatedpatients in the pre-hospital setting. This is one of the reasons why theLondon Ambulance Service and several states in the US have mandatedcapnography for intubated patients in Emergency Medical Services (ambulances).
Gerry Feldman, President of Oridion Capnography, commented that "I ampleased that the Bavarian Red Cross has recognized the importance of CO2monitoring and selected the Microcap. Its superior Microstream capnographyprovides accurate monitoring and many other benefits, and most importantlyits routine use improves patient safety."
Oridion Systems Ltd. (http://www.oridion.comwww.oridion.com) is a globalmedical device company specializing in patient safety monitoring. The Companyoperates through wholly owned subsidiaries in the United States, Europe, andIsrael.
Oridion develops proprietary medical devices and patient interfaces,based on its patented Microstream(R) technologies, for the enhancement ofpatient safety through the monitoring of the carbon dioxide (CO2) in apatient's breath. These products provide effective, proven airway managementand are used in various clinical environments, including procedural sedation,pain management, operating rooms, critical care units, post-anesthesia careunits, emergency medical services, transport, alternate care and othersettings where patients' ventilation may be compromised and at risk.
Certain statements made herein that are not historical areforward-looking. The words "estimate" "project" "intend" "expect" "believe"and similar expressions are intended to identify forward-looking statements.These forward-looking statements involve known and unknown risks anduncertainties. Many factors could cause the actual results, performance orachievements of the Company to be materially different from any futureresults, performance or achievements that may be expressed or implied by suchforward-looking statements, including, among others, our ability to maintainprofits, the market demands for our Capnography products, our ability tofocus our team on the Capnography business, changes in general economic andbusiness conditions, inability to maintain market acceptance to the Company'sproducts, inability to timely develop and introduce new technologies,products and applications, rapid changes in the market for the Company'sproducts, loss of market share and pressure on prices resulting fromcompetition, introduction of competing products by other companies, inabilityto manage growth and expansion, loss of key OEM partners, inability toattract and retain qualified personnel, inability to protect the Company'sproprietary technology.
The Company does not assure any obligation to update the forward lookinginformation contained in this press release.
 Silvestri S, Ralls GA, Krauss B, et al. The effectiveness ofout-of-hospital use of continuous end-tidal carbon dioxide monitoring on therate of unrecognized misplaced intubation within a regional emergency medicalservices system. Ann Emerg Med 45(5):497-503, 2005.
 Miran K, Miljenko K, et al. Partial pressure of end-tidal carbondioxide successful predicts cardiopulmonary resuscitation in the field: aprospective observational study, Critical Care 2008, 12:R115(doi:10.1186/cc7009)For further Oridion information please contact Alan Adler, Chairman and Chief Executive Officer Walter Tabachnik, Chief Financial Officer Elena Gerberg, Investor Relations e-mail: [email protected]
website: http://www.oridion.com phone: +972-2-589-9159 address: Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel
SOURCE Oridion Systems Ltd.